CY1122976T1 - Μαλακες καψουλες καλσιφεδιολης - Google Patents
Μαλακες καψουλες καλσιφεδιοληςInfo
- Publication number
- CY1122976T1 CY1122976T1 CY20201100484T CY201100484T CY1122976T1 CY 1122976 T1 CY1122976 T1 CY 1122976T1 CY 20201100484 T CY20201100484 T CY 20201100484T CY 201100484 T CY201100484 T CY 201100484T CY 1122976 T1 CY1122976 T1 CY 1122976T1
- Authority
- CY
- Cyprus
- Prior art keywords
- soft capsules
- calcifediol
- calcifediol soft
- hypophosphatemia
- osteoarthrosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Lubricants (AREA)
- Carbon And Carbon Compounds (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Paints Or Removers (AREA)
Abstract
Η παρούσα εφεύρεση αναφέρεται σε μαλακές κάψουλες καλσιφεδιόλης, στη χρήση τους για την θεραπεία ή τη πρόληψη νοσημάτων που σχετίζονται με την έλλειψη βιταμίνης D, απομετάλλωση όπως υπασβεστιαιμία και υποφωσφαταιμία, νεφρική οστεοδυστροφία, ραχίτιδα, οστεοπόρωση, οστεοπενία, οστεοαρθρίτιδα, οστεοάρθρωση, οστεομαλακία, υποπαραθυρεοειδισμό, και φλεγμονώδη νόσο του εντέρου, και στις διαδικασίες για τη παρασκευή τους.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15382042.8A EP3053598A1 (en) | 2015-02-06 | 2015-02-06 | Calcifediol soft capsules |
PCT/EP2016/052458 WO2016124724A1 (en) | 2015-02-06 | 2016-02-05 | Calcifediol soft capsules |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1122976T1 true CY1122976T1 (el) | 2021-10-29 |
Family
ID=52462260
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20201100484T CY1122976T1 (el) | 2015-02-06 | 2020-05-28 | Μαλακες καψουλες καλσιφεδιολης |
Country Status (30)
Country | Link |
---|---|
US (1) | US10525018B2 (el) |
EP (3) | EP3053598A1 (el) |
JP (2) | JP6427270B2 (el) |
KR (1) | KR101971384B1 (el) |
CN (2) | CN112843014A (el) |
AU (1) | AU2016214336B2 (el) |
BR (1) | BR112017010657B1 (el) |
CA (1) | CA2967170C (el) |
CL (1) | CL2017001335A1 (el) |
CO (1) | CO2017004545A2 (el) |
CY (1) | CY1122976T1 (el) |
DK (2) | DK3689380T3 (el) |
EA (1) | EA034821B1 (el) |
ES (2) | ES2941385T3 (el) |
HR (1) | HRP20200859T1 (el) |
HU (1) | HUE050133T2 (el) |
LT (1) | LT3204047T (el) |
MA (2) | MA52507A (el) |
MD (1) | MD3204047T2 (el) |
ME (1) | ME03739B (el) |
MX (1) | MX367999B (el) |
MY (1) | MY189432A (el) |
PE (1) | PE20170911A1 (el) |
PH (1) | PH12017501350A1 (el) |
PL (1) | PL3204047T3 (el) |
PT (1) | PT3204047T (el) |
RS (2) | RS64166B1 (el) |
SI (1) | SI3204047T1 (el) |
WO (1) | WO2016124724A1 (el) |
ZA (1) | ZA201703444B (el) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3053598A1 (en) | 2015-02-06 | 2016-08-10 | Faes Farma, S.A. | Calcifediol soft capsules |
CN108542908A (zh) * | 2018-06-08 | 2018-09-18 | 唐飞 | 25-羟基维生素d3在制备治疗或预防肝性骨病药物中的应用 |
CN109662953B (zh) * | 2019-02-18 | 2022-05-10 | 威海金思力生物科技股份有限公司 | 一种维生素d软胶囊及其制作方法 |
WO2021011538A1 (en) * | 2019-07-15 | 2021-01-21 | R.P. Scherer Technologies, Llc | Capsule dosage forms, methods of preparation and methods of use thereof |
CN113559079B (zh) * | 2020-04-28 | 2023-10-20 | 江苏恒瑞医药股份有限公司 | 一种软胶囊及其制备方法和用途 |
WO2022103635A1 (en) * | 2020-11-16 | 2022-05-19 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
WO2022224001A1 (en) | 2021-04-22 | 2022-10-27 | Faes Farma, S.A. | Universal dosage regime of 25-hydroxy vitamin d3 |
CN114159402A (zh) * | 2021-12-21 | 2022-03-11 | 湖州展望天明药业有限公司 | 一种不透明植物胶囊及其制备方法 |
CN114712505B (zh) * | 2022-03-10 | 2023-09-05 | 南方医科大学南方医院 | 维生素d受体激动剂在制备预防和/或治疗炎症性骨丢失的药物中的应用 |
CN116270520A (zh) * | 2023-03-03 | 2023-06-23 | 正大制药(青岛)有限公司 | 一种维生素d胶囊型滴剂及其制备方法 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4532126A (en) * | 1982-05-07 | 1985-07-30 | R. P. Scherer Corporation | Masticatory soft elastic gelatin capsules and method for the manufacture thereof |
GB8305693D0 (en) | 1983-03-02 | 1983-04-07 | Scherer Ltd R P | Pharmaceutical compositions |
JPS6335411A (ja) | 1986-07-29 | 1988-02-16 | Tonen Sekiyukagaku Kk | 高純度合成石英の製造方法 |
US4997824A (en) | 1987-07-22 | 1991-03-05 | Teva Pharmaceutical Industries Ltd. | Combination of cholecalciferol derivatives for the treatment of renal bone disease |
JPH04288016A (ja) | 1991-03-14 | 1992-10-13 | Tokai Capsule Kk | 活性型ビタミンd3類軟カプセル剤の製造方法 |
JPH054925A (ja) | 1991-06-27 | 1993-01-14 | Teikoku Chem Ind Corp Ltd | アルフアカルシドール軟カプセル製剤 |
JP2684587B2 (ja) | 1993-06-21 | 1997-12-03 | 呉羽化学工業株式会社 | 腎性骨異栄養症における骨量減少抑制剤 |
US6340473B1 (en) | 1999-07-07 | 2002-01-22 | R.P. Scherer Technologies, Inc. | Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same |
EP1208843B1 (en) * | 1999-08-31 | 2010-10-13 | Chugai Seiyaku Kabushiki Kaisha | Soft capsules |
US6251426B1 (en) | 1999-09-02 | 2001-06-26 | Banner Pharmacaps, Inc. | Ibuprofen-containing softgels |
IL162213A0 (en) | 2001-12-03 | 2005-11-20 | Novacea Inc | Pharmaceutical compositions containing active vitamin d compounds |
US7632518B2 (en) * | 2002-01-15 | 2009-12-15 | Dsm Ip Assets B.V. | 25-hydroxy vitamin D3 compositions |
US20030158264A1 (en) * | 2002-02-20 | 2003-08-21 | Ramachandran Radhakrishnan | Orally administrable pharmaceutical formulation comprising ephedrine hydrochloride and process for preparing the same |
AU2003230191A1 (en) | 2002-02-20 | 2003-09-09 | Strides Arcolab Limited | Orally administrable pharmaceutical formulation comprising ephedrine hydrochloride and process for preparing the same |
EP1494683A1 (en) | 2002-04-05 | 2005-01-12 | Merck & Co., Inc. | Method for inhibiting bone resorption with an alendronate and vitamin d formulation |
US7438903B2 (en) | 2003-06-06 | 2008-10-21 | Nbty, Inc. | Methods and compositions that enhance bioavailability of coenzyme-Q10 |
PT103177A (pt) | 2003-09-24 | 2005-03-31 | Bioxell Spa | 1-alfa-fluoro-25-hidroxi-16,23e-dieno-26,27-bis-homo-20-epi-colecalciferol, seus sais ou esteres e sua utilizacao no fabrico de medicamentos |
US20050142185A1 (en) | 2003-12-29 | 2005-06-30 | Beleno Alfredo B. | Softgel formulations of bisphosphonates bone resorption inhibitors |
US20050152969A1 (en) | 2004-01-08 | 2005-07-14 | Chiprich Timothy B. | Colored liquid-filled soft capsules and method of manufacture thereof |
US20050175686A1 (en) | 2004-02-11 | 2005-08-11 | Ramachandran Radhakrishnan | Drug delivery system using a solubilized gelatin shell composition and unit dose drug delivery using a special shape soft gelatin capsule |
US20060009425A1 (en) | 2004-05-28 | 2006-01-12 | Leticia Delgado-Herrera | Oral formulations of paricalcitol |
GB2429916A (en) | 2004-06-07 | 2007-03-14 | Strides Arcolab Ltd | Pharmaceutical composition containing a stable and clear solution of anti-inflammatory drug in soft gelatin capsule and process for producing the same |
EP1928471A2 (en) | 2005-09-26 | 2008-06-11 | Novacea, Inc. | Prevention and treatment of gastrointestinal and bladder disorders associated with chemotherapy or radiation therapy using active vitamin d compounds |
US20070098819A1 (en) * | 2005-11-02 | 2007-05-03 | Susan Thys-Jacobs | Micronutrient supplement with calcium, vitamin D or calcium & vitamin D combination for premenstrual syndrome, postpartum depression, depression and panic attacks |
ES2904546T3 (es) * | 2006-02-03 | 2022-04-05 | Opko Renal Llc | Tratamiento de la insuficiencia y deficiencia de vitamina D con 25-hidroxivitamina D2 y 25-hidroxivitamina D3 |
US8501717B2 (en) * | 2007-02-09 | 2013-08-06 | Merck, Sharp & Dohme Corp. | Methods to treat and/or prevent mucositis |
DK2481400T3 (da) * | 2007-04-25 | 2014-09-29 | Opko Ip Holdings Ii Inc | Orale præparater med kontrolleret frigivelse omfattende en vitamin D-forbindelse og en voksagtig bærer |
CA2683628C (en) | 2007-04-25 | 2018-03-06 | Cytochroma Inc. | Method of treating vitamin d insufficiency and deficiency |
US8759328B2 (en) * | 2008-07-24 | 2014-06-24 | Wisconsin Alumni Research Foundation | Once-a-week administration of 25-hydroxy vitamin D3 to sustain elevated steady-state pharmacokinetic blood concentration |
WO2010075065A2 (en) | 2008-12-15 | 2010-07-01 | Banner Pharmacaps, Inc. | Methods for enhancing the release and absorption of water insoluble active agents |
WO2010117873A2 (en) | 2009-04-06 | 2010-10-14 | Banner Pharmacaps, Inc. | Progesterone solutions for increased bioavailability |
WO2012047098A1 (en) | 2010-10-04 | 2012-04-12 | Dishman Pharmaceuticals And Chemicals Ltd. | Encapsulated fat-soluble vitamin |
GB201216385D0 (en) | 2012-09-13 | 2012-10-31 | Chrysalis Pharma Ag | A pharmaceutical composition |
KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 d 방출 제형 |
EP3053598A1 (en) | 2015-02-06 | 2016-08-10 | Faes Farma, S.A. | Calcifediol soft capsules |
-
2015
- 2015-02-06 EP EP15382042.8A patent/EP3053598A1/en not_active Withdrawn
-
2016
- 2016-02-05 EP EP16702960.2A patent/EP3204047B1/en active Active
- 2016-02-05 PE PE2017000841A patent/PE20170911A1/es unknown
- 2016-02-05 MA MA052507A patent/MA52507A/fr unknown
- 2016-02-05 LT LTEP16702960.2T patent/LT3204047T/lt unknown
- 2016-02-05 ES ES20163569T patent/ES2941385T3/es active Active
- 2016-02-05 PT PT167029602T patent/PT3204047T/pt unknown
- 2016-02-05 ME MEP-2020-108A patent/ME03739B/me unknown
- 2016-02-05 AU AU2016214336A patent/AU2016214336B2/en active Active
- 2016-02-05 DK DK20163569.5T patent/DK3689380T3/da active
- 2016-02-05 WO PCT/EP2016/052458 patent/WO2016124724A1/en active Application Filing
- 2016-02-05 EP EP20163569.5A patent/EP3689380B1/en not_active Revoked
- 2016-02-05 US US15/524,174 patent/US10525018B2/en active Active
- 2016-02-05 CA CA2967170A patent/CA2967170C/en active Active
- 2016-02-05 SI SI201630778T patent/SI3204047T1/sl unknown
- 2016-02-05 RS RS20230331A patent/RS64166B1/sr unknown
- 2016-02-05 HU HUE16702960A patent/HUE050133T2/hu unknown
- 2016-02-05 ES ES16702960T patent/ES2738642T3/es active Active
- 2016-02-05 EA EA201791097A patent/EA034821B1/ru unknown
- 2016-02-05 MY MYPI2017702240A patent/MY189432A/en unknown
- 2016-02-05 DK DK16702960.2T patent/DK3204047T3/da active
- 2016-02-05 CN CN202110038958.XA patent/CN112843014A/zh active Pending
- 2016-02-05 MD MDE20170056T patent/MD3204047T2/ro unknown
- 2016-02-05 MX MX2017006272A patent/MX367999B/es active IP Right Grant
- 2016-02-05 MA MA41058A patent/MA41058B1/fr unknown
- 2016-02-05 BR BR112017010657-4A patent/BR112017010657B1/pt active IP Right Grant
- 2016-02-05 JP JP2017525563A patent/JP6427270B2/ja active Active
- 2016-02-05 RS RS20200628A patent/RS60467B1/sr unknown
- 2016-02-05 PL PL16702960T patent/PL3204047T3/pl unknown
- 2016-02-05 CN CN201680004162.XA patent/CN106999441B/zh active Active
- 2016-02-05 KR KR1020177012947A patent/KR101971384B1/ko active IP Right Review Request
-
2017
- 2017-05-05 CO CONC2017/0004545A patent/CO2017004545A2/es unknown
- 2017-05-18 ZA ZA2017/03444A patent/ZA201703444B/en unknown
- 2017-05-24 CL CL2017001335A patent/CL2017001335A1/es unknown
- 2017-07-28 PH PH12017501350A patent/PH12017501350A1/en unknown
-
2018
- 2018-07-27 JP JP2018141114A patent/JP6697779B2/ja active Active
-
2020
- 2020-05-28 HR HRP20200859TT patent/HRP20200859T1/hr unknown
- 2020-05-28 CY CY20201100484T patent/CY1122976T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1122976T1 (el) | Μαλακες καψουλες καλσιφεδιολης | |
CY1124886T1 (el) | Χιμαιρικοι υποδοχεις αντιγονου bcma | |
CY1123853T1 (el) | Ρυθμιστες nrf2 | |
CL2018001545A1 (es) | Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas | |
CO2017005784A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
CL2016001154A1 (es) | Composiciones para prevenir o tratar alergias en infantes a partir de o alimentados por madres no secretoras. | |
BR112017020893A2 (pt) | método para o tratamento de câncer | |
EA201791485A1 (ru) | Анти-cd47-антитела и их применения | |
BR112018003212A2 (pt) | diacereína ou seus análogos para inibir a expressão de asc, expressão de nlrp3 e / ou formação de complexo inflamassoma nlrp3 | |
BR112017023853A2 (pt) | composições de nanopartícula para terapia sustentada. | |
CO2017007121A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
EA201790273A1 (ru) | Флагеллиновые композиции и их применение | |
CL2018000597A1 (es) | Métodos para tratar enfermedades inflamatorias | |
CY1125150T1 (el) | Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου | |
CY1120459T1 (el) | Αντισωματα των χημειοκινων παν-elr+ cxc | |
SV2017005412A (es) | Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos | |
DK3379963T3 (da) | Sål, især til sko | |
EA201791845A1 (ru) | Твердые формы менахинолов | |
AR107786A1 (es) | Métodos y composiciones para la detección y el diagnóstico de enfermedad renal y enfermedad periodontal | |
BR112018000217A2 (pt) | sistemas de distribuição de nanopartículas aperfeiçoados | |
EA201790156A1 (ru) | Азетидинилоксифенилпирролидиновые соединения | |
CO2017010621A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
BR112017011285A2 (pt) | compostos intermediários para produzir ingredientes de perfumaria | |
CY1122935T1 (el) | Ενισχυτικα της υδατοδιαλυτοτητας που βασιζονται στο γλυκογονο | |
CL2018001370A1 (es) | Derivados novedosos de diamino piridina |